News

Promising Developments in Hepatocellular Carcinoma Treatments

Promising Developments in Hepatocellular Carcinoma Treatments

SCG Presents Breakthrough Data on SCG101 in Liver Cancer Therapy

Today, SCG Cell Therapy Pte Ltd, a pioneering biotechnology firm specializing in TCR T cell therapy for infectious diseases and cancers, unveiled its latest findings from a Phase 1 trial featuring SCG101, an innovative HBV-specific TCR-T cell therapy targeted at advanced HBV-related hepatocellular carcinoma (HCC). These developments were showcased at a prominent medical congress.

Key Efficacy Results from the SCG101 Trial

The trial's outcomes revealed that SCG101 achieved significant clearance of serum hepatitis B surface antigen (HBsAg) and HBV-DNA levels in patients with advanced HBV-related HCC who had previously undergone extensive treatment. Impressively, 94% of the participants had been treated with nucleoside analogue (NA) antiviral therapies, and 72% were noted to have liver cirrhosis at the start. Following a single infusion of SCG101, patients experienced rapid and substantial declines in serum HBsAg levels, with 94% of individuals achieving reductions ranging from 1.0 to 4.6 log?? in just 28 days and maintaining levels below 100 IU/mL for periods extending up to one year. Remarkably, 23.5% of patients reported complete HBsAg loss.

Antitumor Activity and Patient Outcomes

Beyond its antiviral potential, SCG101 made strides in demonstrating antitumor efficacy. Each participant had previously undergone at least two lines of systemic cancer therapies, including immune checkpoint inhibitors. Despite the challenges posed by this heavily pre-treated cohort, 47% of patients (8 out of 17) showed measurable tumor regression. As of the latest review, the median overall survival (OS) has not yet been finalized.

Safety Profile of SCG101

Overall, SCG101 was generally well tolerated among trial subjects, maintaining a favorable safety profile. Transient elevation in alanine aminotransferase (ALT) levels was reported in 94% of patients, a response consistent with the cytolytic action of the therapy, and these elevations resolved within two weeks. Common treatment-related adverse events (TRAEs) included cytokine release syndrome (CRS), neutropenia, and thrombocytopenia, all of which were manageable and reversible.

Expert Insights on SCG101's Potential

Prof. Dr. Shunda Du, Chief of Liver Surgery Department from a leading academic hospital, commented on the dual antiviral and antitumor effects of SCG101, expressing optimism about its potential as an innovative immunotherapeutic option for patients suffering from HBV-related HCC. He emphasized that the sustained clearance of HBsAg coupled with observable tumor responses signifies a promising advancement in addressing a significant clinical demand.

Understanding Hepatitis B and Its Impact

Globally, Hepatitis B (HBV) poses a substantial health challenge, impacting over 250 million individuals. This virus is a leading contributory factor for liver cancer, accounting for between 50% and 80% of HCC cases worldwide. Chronic HBV infections can lead to the incorporation of HBV DNA into the host's genome, maintaining HBsAg expression, promoting chromosomal instability, and triggering oncogene activation, all of which heighten the risk of developing HCC.

Mechanism of Action for SCG101

SCG101 is tailored to specifically target and eliminate HBV-infected hepatocytes and HCC cells through the recognition of specific epitopes of the HBV surface antigen (HBsAg) displayed by the major histocompatibility complex (MHC). By utilizing both cytolytic and non-cytolytic mechanisms, SCG101 effectively clears HBV-infected hepatocytes along with premalignant and HBV-HCC cells that exhibit HBV-DNA integration.

Future Directions for SCG101

Christy Ma, Chief Executive Officer of SCG Cell Therapy, remarked on the significance of these findings in the ongoing development of SCG101 and highlighted the need for precision T cell therapies aimed at chronic HBV infections and their related liver cancers. SCG101 stands out as the inaugural TCR-T cell therapy to show both virologic clearance and tumor regression among patients with HBV-related HCC, fueling expectations for its advancement into further clinical stages to offer a transformative solution for those affected.

Frequently Asked Questions

What is SCG101?

SCG101 is a TCR-T cell therapy designed to target HBV-infected cells and effectively contribute to tumor regression in patients with related cancers.

What was the trial's key finding?

The trial revealed that SCG101 achieved significant HBsAg clearance and tumor regression in a patient population heavily pre-treated for liver cancer.

How well was SCG101 tolerated by patients?

The treatment exhibited a favorable safety profile, with manageable side effects that resolved promptly after treatment.

What are the implications of these findings?

The results point towards SCG101 as a potential breakthrough therapy for patients who have limited options due to advanced HBV-related cancers.

How does SCG101 work?

SCG101 targets specific epitopes of HBsAg to eliminate HBV-infected cells through immune-mediated mechanisms, addressing serious viral infections and cancer.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 116

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 174

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 9

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 73

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 160

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 40

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading

Top 5 Most Recently Viewed Articles

Fujitsu Enhances ETF Trading with New ASX Partnership

Updated Category News Views 212

Fujitsu Partners with ASX for ETF Trading Innovation Fujitsu Limited is teaming up with the Australian Securities Exchange (ASX) and the Tokyo Stock Exchange (TSE) to create a state-of-the-art SaaS-based Request for Quote (RFQ) platform. This exciting initiative represents a significant step forward in modernizing the ETF trading landscape. Understanding the New RFQ...

Continue Reading
Owens Corning Reports Strong Earnings and Future Outlook

Updated Category News Views 177

Owens Corning Shows Strong Performance in Recent Quarter Owens Corning (NYSE: OC) has exceeded expectations with its recent earnings results, garnering significant attention from investors. The company reported exceptionally strong numbers from its latest earnings announcement, which prompted a notable increase in its stock price. The performance indicates solid...

Continue Reading
Research Links Chorioamnionitis to Preterm Birth Developments

Updated Category News Views 182

Chorioamnionitis and Its Impact on Early Birth Recent research emphasizes the severe implications of moderate to severe chorioamnionitis (HCA) associated with preterm births. Experts from Cincinnati Children's Hospital have confirmed that these infections not only trigger preterm deliveries but also lead to significant neurodevelopmental issues in early childhood. Study...

Continue Reading
Micron Shifts Focus: Exiting Consumer Market for AI Future

Updated Category News Views 305

Micron Technology's Significant Move Micron Technology, Inc. (NASDAQ: MU) has announced a strategic decision to exit its Crucial consumer business, ceasing the sale of Crucial-branded products through various global retailers and distributors. This transition marks a significant pivot aimed at refocusing efforts toward emerging market opportunities, especially in...

Continue Reading
China's COMAC Strives for Growth in Vietnam's Aviation Sector

Updated Category News Views 449

China's Ambitious Move into Vietnam's Aviation Market China's state-owned aircraft manufacturer, COMAC, is making significant strides to penetrate the international aviation market. The focus is currently on gaining approval for its C909 jets in Vietnam, a move indicative of a broader strategy to enhance its global presence. This initiative highlights the ongoing...

Continue Reading